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Backround/aim: In this study, the efficacy of an IL-6 antagonist, Tocilizumab, administered in the early period was studied in intensive
care patients with COVID-19 pneumonia followed by hypoxic and systemic inflammation not receiving mechanical ventilation support.
Materials and methods: Patients with COVID-19 pneumonia who have signs of hypoxia and systemic inflammation and/or who have
acute bilateral infiltrates on chest radiograph and who received tocilizumab treatment were compared with the patients who received
standard medical therapy. Patients who were followed up with COVID-19 pneumonia and respiratory failure between March 2020
and March 2021 were retrospectively evaluated in the study. A 400 mg – 800 mg iv dose (depending on weight) of Tocilizumab was
administered. The primary endpoint was determined as intensive care unit mortality.
Results: A total of 213 patients who were admitted with respiratory failure associated with COVID-19 to our third-level intensive care
unit were evaluated. Of these patients, the study was conducted with 50 patients in the tocilizumab treatment group and 92 patients in the
standard treatment group. During the intensive care period, 26 patients (28.3%) in the standard treatment group and 12 patients (24%)
in the group receiving tocilizumab died. The adjusted hazard ratio for mortality in the tocilizumab group was 0.39 (95% confidence
interval [CI], 0.186 to 0.808; p = 0.001 by log-rank test). During the intensive care period, 22 patients (24.8%) in the standart treatment
group and 16 patients (32%) in the tocilizumab group were intubated. The adjusted hazard ratio for a primary outcome intubation in
the tocilizumab group was 0.71 (95% confidence interval [CI], 0.355 to 1.424; p = 0.184 by log-rank test).
Conclusion: Tocilizumab was administered with a low-dose steroid or following pulse steroid in intensive care patients followed up with
COVID-19 pneumonia and evidence of hypoxia, and systemic inflammation was shown to reduce the intensive care all-cause mortality.
Key words: Antibodies, COVID-19, intensive care unit, mortality, SARS-COV-2, tocilizumab

1. Introduction
Coronavirus disease 2019 (Covid-19) emerged in China
in December 2019 and quickly led to a public health
emergency1 [1]. The clinical spectrum of patients ranged
from severe (14%) and critical (5%) cases of Covid-19
pneumonia to acute respiratory distress syndrome (ARDS)
[2,3]. ARDS is the primary cause of poor prognosis in terms
of mortality and morbidity in most of these patients. One

potential consequence of COVID-19 is cytokine release
syndrome (CRS), and its most severe form is secondary
hemophagocytic lymphohistiocytosis. These syndromes
are characterized by excessive inflammatory cytokine
production. The cytokines most blamed for this cytokine
storm are IL-6, IL-10, and tumor necrosis factor-a (TNF-a).
Of these, IL-6 has been identified as a central player in
toxicity due to its inflammatory properties through two

WHO. World Health Organization (2021). COVID-19 Public Health Emergency of International Concern (PHEIC) Global research and innovation
forum [online]. Website https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-globalresearch-and-innovation-forum [accessed May 4, 2021].
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signalling pathways: 1- the classical pathway and 2- the
associated soluble receptor pathway. The onset of the
pro-inflammatory response is determined by a significant
increase in IL-6 levels. The plasma levels of IL-6 are also
directly related to an increase of other inflammatory
parameters in the blood, such as C-reactive protein (CRP),
lactate dehydrogenase (LDH), and D-dimer [4].
Therefore, anti-cytokine therapies have been
recommended as a treatment strategy in eligible COVID-19
patients [5–8]. Tocilizumab is a potential treatment option
although its safety and efficacy in the COVID-19 patient
population is still unclear. Tocilizumab is a US Food and
Drug Administration approved IL-6 receptor antagonist
widely used to treat CRS secondary to the chimeric antigen
receptor T cell [9]. One of the advantages of tocilizumab is
its long half-life, and its irreversible effect on IL-6 receptors
in both the membrane-bound and soluble forms [10]. In
the literature, studies using Tocilizumab in the treatment
of COVID-19 have different clinical results [11–14].
According to the RECOVERY trial results, one of the most
comprehensive of these studies, tocilizumab reduced the
risk of death when given to hospitalized patients with
severe COVID-19. The study also showed that tocilizumab
shortened the time patients were successfully discharged
from hospital and reduced the need for a mechanical
ventilator. In this study, which included 177 centers and
35,000 patients in the UK, 2022 patients were included in
the tocilizumab group and 2094 patients were included in
the standard treatment group. Treatment with tocilizumab
significantly reduced deaths: 596 (29%) of the patients in
the tocilizumab group died within 28 days compared with
694 (33%) patients in the standard treatment group (rate
ratio 0.86; [95% confidence interval (CI) 0 77 to 0.96]; p
= 0.007), an absolute difference of 4%. This result is quite
remarkable and promising.
The aim of this study was to report our experience with
a series of COVID-19 patients treated in intensive care
unit with tocilizumab. In this study, the effectiveness of
tocilizumab treatment was evaluated in patients who were
admitted to intensive care due to respiratory failure but did
not need mechanical ventilation.
2. Materials and methods
2.1. Study group
The STROBE guideline was used as a guide for this
manuscript. This study was carried out in Karadeniz
Technical University Faculty of Medicine, a third-level,
16-bed Intensive Care Unit. The study was started after
obtaining the approval of the local ethics committee
(protocol number: 2021/24 date: 22.02.2021) and

the Scientific Research Committee of the Ministry of
Health with nº 2021-01-24T17_19_44. The study was
also registered on the ClinicalTrials with protocol nº
NCT04893031. In this study, COVID-19 pneumonia and
respiratory failure cases admitted to our intensive care unit
between March 2020 and March 2021 were retrospectively
analyzed. The investigators designed the trial, collected the
data, and performed the analysis. All cases were diagnosed
based on typical radiological image using computed
tomography (CT) or on the real time polymerase chain
reaction (PCR) for Sars-CoV2 infection. The patients with
severe and critical COVID-19 pneumonia were admitted
to our intensive care unit. Severe illness, clinical signs of
pneumonia (fever, cough, dyspnea, tachypnea), and one
of the following: respiratory rate > 30 breaths/min, severe
respiratory distress; or SpO2 < 90% on room air and, and
presence of critical illness ARDS or respiratory failure
requiring ventilation was defined as sepsis or septic shock
[15]. These patients generally required high flow nasal
cannula or invasive/noninvasive mechanical ventilation
due to respiratory failure. The patients were followed until
discharge from the intensive care unit or their death.
2.1.1. Tocilizumab group:
The patients with signs of hypoxia and systemic
inflammation (SpO2 <90% on room air with an elevation
of any two of the systemic inflammatory markers such as
CRP, LDH and Ferritin) and/or acute onset of bilateral
infiltrates on chest X-ray or rapid progression of existing
infiltrates but who did not require mechanical ventilation
at intensive care admission and were treated with
tocilizumab.
2.1.1. Standard treatment group
The patients who did not require mechanical ventilation
in intensive care admission and who did not receive
tocilizumab treatment at any period of hospitalization.
2.2. Exclusion criteria
The patients requiring mechanical ventilation during
intensive care admission, patients <18 years of age, cases
who received tocilizumab after being intubated during
follow-up even though they were not intubated at admission,
patients for whom tocilizumab is contraindicated2. The
patients in the study group are shown in Figure 1.
2.3. Tocilizumab treatment approach
Treatment was initiated by detail explanation of the risks
and benefits of tocilizumab to the patients or their firstdegree relatives by obtaining approved consent. Signs of
hypoxia and systemic inflammation (SpO2 <90% on room
air and accompanying elevation of any two of the systemic
inflammatory markers such as CRP, LDH and Ferritin)

T.C. Sağlık Bakanlığı, Bilimsel Danışma Kurulu Çalışması (2020). Antisitokin-Antiinflamatuar Tedaviler, Koagülopati Yönetimi: Turkey [online].
Website moz-extension://1e25cedd-d1b7-894e-bbbd-18c83968a692/enhanced-reader.html?open App&pdf=https%3A%2F%2Fcovid19.saglik.gov.
tr%2FEklenti%2F39296%2F0%2Fcovid-19rehberiantisitokin-antiinflamatuartedavilerkoagulopatiyonetimipdf.pdf [accessed May 4, 2021].
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1
Figure 1. Study groups flow diagram.

and/or acute bilateral infiltrations or rapid progression
of existing infiltrations on chest radiography, without
waiting to meet all of the Cytokine release syndrome
(CRS) criteria, and with major treatment indications for
tocilizumab treatment in our clinic.
Radiological follow-up was performed by daily
bedside anteroposterior chest radiographs. The follow
up inflammatory parameters are CRP, ferritin, and LDH
levels. The increase in any two of these markers were
considered significant for the inflammatory process. Since
the IL-6 kit is not always available, it was not used in every
patient. Tocilizumab dose was determined as 1 hour 8 mg/
kg i.v. infusion (at a dose of 400–800 mg). A second dose
was administered to some patients at 12–24 h intervals
depending on the changes in their clinical condition.
The contraindications for tocilizumab are determined
as increased procalcitonin levels with positive cultures
(blood, urine, or sputum), indicating a suspected
or confirmed bacterial infection, pregnancy, active
tuberculosis, active hepatitis B-C, known allergy, and
hypersensitivity3. Liver function tests and platelet counts
were closely monitored during follow-up. All patients who
received tocilizumab also received our standard treatment
protocol which is; antiviral therapy (favipravir), low dose

methylprednisolone (1–2 mg / kg) or pulse steroid (250 mg
/ day for 3 days) according to the clinical severity of disease,
anticoagulant, vitamin C and vitamin D supplements. All
patients who could adapt and benefit were followed in the
prone/ semiprone position.
2.4. Follow-up parameters:
Demographic characteristics of the patients, comorbidities,
applied COVID-19 specific treatments, laboratory
parameters at first admission, radiological evaluations,
type of respiratory support given at the time of admission
and during follow-up, on which day of the intensive care
admission tocilizumab was given, arterial blood gas and
PaO2/FiO2 values at the time of admission were recorded.
The mortality and organ failure scores (Apache II and
SOFA) of patients during ICU admissions, length of stay
in intensive care unit, and patient outcomes were obtained
from the medical records.
2.5. Study outcomes
The primary outcome of the study was the condition of
all-cause mortality in tocilizumab and standard therapy
patient groups. The secondary outcome was intubation in
the tocilizumab or standard treatment group as assessed
by an event-time analysis.

T.C. Sağlık Bakanlığı, Bilimsel Danışma Kurulu Çalışması (2020). Antisitokin-Antiinflamatuar Tedaviler, Koagülopati Yönetimi: Turkey [online].
Website moz-extension://1e25cedd-d1b7-894e-bbbd-18c83968a692/enhanced-reader.html?open App&pdf=https%3A%2F%2Fcovid19.saglik.gov.
tr%2FEklenti%2F39296%2F0%2Fcovid-19rehberiantisitokin-antiinflamatuartedavilerkoagulopatiyonetimipdf.pdf [accessed May 4, 2021].
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2.6. Statistical analysis
Data were analyzed with IBM SPSS V23 (Chicago,
USA). Variables are examined by Shapiro – Wilk and
Kolmogorov–Smirnov tests for the distributions.
Continuous variables are expressed as mean ± standard
deviation, or as median (interquartile range). The
Student’s t test or the Mann–Whitney test was used to
make comparisons. Categorical variables are presented as
numbers (proportions) and were compared with the chi
square test or the Fisher’s exact test where appropriate.
Efficacy analyses were performed in the treat population
with patients grouped according to treatment assignment.
Analyses were adjusted according with APACHE II score.
The primary outcome was estimated with the Kaplan
– Meier method, and cumulative survive curves were
compared between the groups with the stratified log-rank
test. The stratified Cox proportional-hazards model was
used to estimate the hazard ratio and 95% confidence
interval. In this analysis, data on patients who survived
and did not receive mechanical ventilation on or during
intensive care unit stay were censored at the discharge
from ICU. The primary and key secondary outcomes were
evaluated in a hierarchical manner to control the overall
trial-wide type I error rate at the 5% significance level.
3. Results
During the study period, 213 intensive care patients were
evaluated in terms of eligibility for the study. Thirty-six
patients were excluded from the study because they were
supported by invasive mechanical ventilation at the time
of admission to the intensive care unit. While 63 out of 177
patients received tocilizumab treatment, 114 patients did
not receive tocilizumab treatment. In the tocilizumab group,
13 patients, who received treatment after being connected
to an invasive mechanical ventilator, and 22 patients in the
group who did not receive tocilizumab because of various
reasons (16 patients with active infection, 6 patients with
terminal disease, malignancy) were excluded from the
study. Study analyzes were conducted with 50 patients
receiving tocilizumab and 92 patients receiving only
standard medical therapy (Figure 1).
The baseline characteristics of the patients are shown
in Table 1. Ninety-five (66.9%) of the patients included in
the population were male and 47 (33.1%) were female. The
mean age was 62.94 ± 14.28 years. The youngest patient
was 20 years old, and the oldest patient was 92 years old.
Fifty-five of the patients (41.4%) had A rh (+) blood group
and 39 (27.5%) of the patients were smokers, while 84
(54.2%) of them were alcohol consumers. While 104 of
the patients (73.2%) had comorbidity, the most common
comorbidity was hypertension in 82 (57.7%) patients. The
baseline demographic and disease characteristics were
generally balanced in the two groups. In the standard
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treatment (ST) and tocilizumab treatment (TT) groups, 22
patients (23.9%) and 8 patients (16%), respectively, used
acetylsalicylic acid in their daily life, while 25 (27.2%)
and 5 (10%) used ACE inhibitors, respectively. In the ST
and TT groups, 19 patients (20.7%) and 6 patients (12%),
respectively, had vaccinated Influenza vaccine, 12 patients
(13%) and 2 patients (4%) had vaccinated Pneumococcal
vaccine, respectively. The median concentration of
laboratory values of groups was shown in Table 1. Serum
median albumin level was statistically higher in the TT
group with 32.6 g / L (IQR: 30.35–34.35) compared to
the ST group 30 g / L (IQR: 27.95–33.6) (p = 0.030). The
median scores of SOFA in the ST and TT groups were 3
(IQR: 2–4), 2.5 (IQR: 1–3.25), respectively (p = 0.207). The
median scores of APACHE II in the ST and TT groups were
8 (IQR: 3.25–13) and 8 (IQR: 3.75–11.25), respectively (p
= 0.774).
3.1. Primary and seconder endpoint
From the study patients, a total of 38 patients (26.7%)
died in the intensive care unit (Table 2), 26 patients
(28.3%) in the ST group and 12 patients (24%) in the
TT group, respectively. The Kaplan–Meier curves for the
time to death are shown in Figure 2A. The hazard ratio
was estimated with adjustment for APACHE II score. The
adjusted hazard ratio for a primary outcome mortality
event in the tocilizumab treatment group was 0.39 (95%
confidence interval [CI], 0.186 to 0.808; p = 0.001 by logrank test). A total of 38 patients (26.7%) were intubated
in the intensive care unit (Table 2), 22 patients (24.8%)
were in the ST group and 16 patients (32%) were in the TT
group. The Kaplan–Meier curves for the time to intubation
are shown in Figure 2B. The hazard ratio was estimated
with adjustment for APACHE II score. The adjusted
hazard ratio for a primary outcome intubation event in the
tocilizumab treatment group was 0.71 (95% confidence
interval [CI], 0.355 to 1.424; p = 0.184 by log-rank test).
Four groups as those who only take pulse steroids, those
who only take tocilizumab, those who take both, and
those who do not take both were created according to
treatments. Mortality rates and occurrence time between
subgroups were analyzed by Kaplan–Meier curves (Table
2 and Figure 2C). The hazard ratio was estimated with
adjustment for APACHE II score. The group that received
no treatment was considered as the base group and when
the cox-regression analysis was compared with this base
group the adjusted hazard ratio for a primary outcome
mortality event in the pulse steroid treatment group was
1.13 (95% confidence interval [CI], 0.353 to 3.628), in the
tocilizumab treatment group was 0.34 (95% confidence
interval [CI], 0.132 to 0.854) and in the treatment with
both group was 0.5 (95% confidence interval [CI], 0.185
to 1.355), p = 0.001 by log-rank test. Time dependent
mortality rates were statistically and significantly lower
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Table 1. Baseline Characteristics of the Patients.*
Tocilizumab Treatmnet
(TT)
(N = 50)
56.86 ± 15.46

Total
(N = 142)
62.94 ± 14.28

p Value

Age, mean ± std dev − yr

Standart Treatment
(ST)
(N = 92)
66.24 ± 12.48

Male sex − no. (%)

58 (63.04)

37 (74)

95 (66.9)

0.255

A rh+ blood type − no. (%)

37 (42)

18 (40)

55 (41.4)

0.968

Height, mean ± SD − cm

168.5 ± 8.07

171.69 ± 9.45

169.61 ± 8.68

0.048

Weight, mean ± SD − kg

82.75 ± 12.37

85.67 ± 13.13

83.77 ± 12.67

0.193

Smoking − no. (%)

26 (28.3)

13 (26)

39 (27.5)

0.927

Cigarette, median (IQR) − pocket/yr

37.5 (30 — 50)

30 (16.25 – 40)

32.5 (30 − 48.75)

0.029

Alcohol using − no. (%)

61 (66.3)

23 (46)

84 (59.2)

0.019

Present of any comorbidity

73 (79.3)

31 (62)

104 (73.2)

0.042

Present of cardiovascular comorbidity

61 (66.3)

24 (48)

85 (59.9)

0.052

Hypertension

59 (64.1)

23 (46)

82 (57.7)

0.056

Present of respiratory comorbidity

20 (21.7)

7 (14)

27 (19)

0.369

Acetylsalicylic acid

22 (23.9)

8 (16)

30 (21.1)

0.374

ACE inhibitors

25 (27.2)

5 (10)

30 (21.1)

0.029

Influenza vaccine

19 (20.7)

6 (12)

25 (17.6)

0.288

Pneumococcal vaccine

12 (13)

2 (4)

14 (9.9)

0.138

C−reactive protein level − mg/L

105.3 (46 − 168.7)

139.4 (68.6 − 182.5)

116.15 (61.5 − 176.6)

0.067

White blood cell count − cells/mm3

10160
(6862.5 − 13217.5)

12630
(7855 − 15660)

10710
(7015 − 14040)

0.080

Neutrophil ratio − %

90.2 (84.68 − 93)

90.9 (87.2 − 93.45)

90.4 (85.75 − 93.2)

0.230

Lymphocyte ratio − %

6.3 (3.93 − 9.45)

5.2 (3.45 − 8.45)

5.9 (3.7 − 9.1)

0.212

Neutrophil to lymphocyte ratio

14.91 (9.19 − 26.14)

17.6 (10.09 − 26.37)

15.24 (9.5 − 26.22)

0.359

Platelet count − 103 cells/mm3

223 (166.25 − 294)

237 (165.5 − 318.5)

233 (166 − 297.5)

0.550

Platelet to lymphocyte ratio

413.45
(246.43 − 599.5)

392.1
(263.9 − 582.83)

413
(254.5 − 586.08)

0.950

Albumine level − g/L

30 (27.95 − 33.6)

32.6 (30.35 − 34.35)

31.3 (29.1 − 34)

0.030

Procalcitonin level − µg/L

0.17 (0.08 − 0.63)

0.15 (0.12 − 0.25)

0.17 (0.1 − 0.41)

0.505

Blood urea nitrogen level − mg/dL

25 (18 − 37)

21 (14.75 − 27)

23 (17 − 34)

0.006

Creatinine level − mg/dL

0.92 (0.75 − 1.2)

0.85 (0.69 − 1.07)

0.9 (0.71 − 1.12)

0.184

Lactate dehydrogenase level − U/L

456 (359 − 590)

522 (417 − 712)

477 (380 − 618.25)

0.024

D−dimer level − mg/L

1.2 (0.68 − 3.53)

0.94 (0.54 − 1.83)

1.01 (0.62 − 2.65)

0.097

Troponin level − ng/L

11.65 (6.03 − 47.19)

7.13 (4.48 − 11.67)

9.84 (5.09 − 28.39)

0.007

Lactate level − mg/dL

16 (12 − 25.75)

16.5 (12.75 − 24)

16 (12 − 24.25)

0.599

Ferritin level − µg/L

604.5
(273.15 − 1055.5)

931
(516.3 − 1240.2)

680
(349.55 − 1114.75)

0.022

Characteristic

<0.001

Comorbidity − no. (%)

Drugs or vaccine − no. (%)

Median laboratory values (IQR) †

Median arterial blood gas values on day 1 under invasive mechanical ventilation (IQR) ‡
pH value

7.44 (7.41 − 7.49)

7.45 (7.4 − 7.48)

7.44 (7.41 − 7.49)

0.901

FiO2 support − %

80 (60 − 83)

80 (60 − 92.5)

80 (60 − 85)

0.072
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Table 1. (Continued).
P/F ratio

87.8 (68.15 − 131.25)

79.5 (57.75 − 98.5)

85.5 (68 − 122.25)

0.040

PO2 value − mmHg

65.7 (55.5 − 75)

60.2 (52.98 − 69.33)

63.2 (55.05 − 74.2)

0.139

pCO2 value − mmHg

35.3 (31.5 − 39.6)

37.85 (34.73 − 43.48)

36.8 (33.05 − 40)

0.062

HCO3 value − mmol/L

24.8 (23.2 − 27.4)

26.65 (25.08 − 27.75)

25.5 (23.5 − 27.6)

0.051

sO2 value − %

93 (88 − 95.5)

90.95 (86.53 − 94.23)

92 (87.9 − 95.15)

0.070

SOFA

3 (2 − 4)

2.5 (1 − 3.25)

3 (1 − 4)

0.207

APACHE II

8 (3.25 − 13)

8 (3.75 − 11.25)

8 (3.75 − 13)

0.774

Median score points (IQR)

*Percentages may not total 100 because of rounding. IQR denotes interquartile range, FiO2 fraction of inspired oxygen, The P/F ratio
equals the arterial pO2 divided by the FiO2, PO2 partial pressure of oxygen, pCO2 partial pressure of carbon dioxide, sO2 arterial oxygen
saturation, SOFA sequential organ failure assessment, and APACHE II acute physiology and chronic health evaluation II.
† C−reactive protein levels were missing for 4 patients (3 in the ST group and 1 in the TT group), Albumine levels were missing for 7
patients (6 in the ST group and 1 in the TT group), Procalcitonin levels were missing for 16 patients (13 in the ST group and 1 in the TT
group), Lactate dehydrogenase levels were missing for 8 patients (5 in the ST group and 3 in the TT group), D−dimer levels were missing
for 12 patients (7 in the ST group and 5 in the TT group), Troponin levels were missing for 41 patients (25 in the ST group and 16 in the
TT group), Ferritin levels were missing for 29 patients (22 in the ST group and 7 in the TT group).
‡ 22 patients were intubated in the ST group and 16 patients were intubated in the TT group.
Table 2. Time−to−Event outcomes in the treat population.*
No. of Patients with
event within ICU Stay (%)

Median No. of days
to event (95% CI) †

Adj. Hazard Ratio
(95% CI) ‡

Log−Rank
P Value ¶

Standart Treatment (N = 92)

26 (28.3)

14 (6.643 − 21.357)

0.39 (0.186 − 0.808)

0.001

Tocilizumab Treatment (N = 50)

12 (24)

36 (11.781 − 60.219)

Standart Treatment (N = 92)

22 (24.8)

20 (3.222 − 36.778)

0.71 (0.355 − 1.424)

0.184

Tocilizumab Treatment (N = 50)

16 (32)

17 (NE − NE)

Standart Treatment (N = 72)

22 (30.6)

12 (8.552 − 15.448)

Pulse steroid Treatment (N = 20)

4 (20.0)

19 (NE − NE)

1.13 (0.353 − 3.628)

Tocilizumab Treatment (N = 28)

6 (21.4)

36 (NE − NE)

0.34 (0.132 − 0.854)

Both Treatment (N = 22)

6 (27.3)

NE (NE − NE)

0.5 (0.185 − 1.355)

Primary outcome
Mortality

Invaziv mechanical ventilation

Mortality Subgroup §
0.005

*The treat population included the 142 patients (50 in the tocilizumab group and 92 in the not received tocilizumab group) who
underwent study and received either tocilizumab or not before intubation or death. ICU denotes intensive care unit, Adj adjusted, and
NE could not be estimated.
† The median time to an outcome event was estimated with the Kaplan–Meier approach.
‡ The adjusted Cox proportional−hazards model with APACHE II as an adjusteded factor was used to estimate the hazard ratio and 95%
confidence interval. For APACHE II score 95% CI was 1.1 (1.045−1.156) in mortality outcome. For APACHE II score 95% CI was 1.11
(1.057−1.165) in invasive mechanical ventilatory outcome. For APACHE II score 95% CI was 1.1 (1.045−1.167) in mortality outcome
between subgroups.
¶ The P value was calculated with the log−rank test. Significance testing was performed hierarchically to control the trial−wide type I
error rate at a 5% significance level.
§ Each group was compared with the Standart Treatment group in the cox regression analyses.

only in the tocilizumab group compared to the other
groups. In the regression analysis performed in the
tocilizumab patient group, no significant relationship was

44

found between the day of tocilizumab administration after
hospitalization in the intensive care unit and mortality.
[β=0.848 (C.I. %95; 0.562–1.279) p = 0.210]
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1

Figure 2. Kaplan–Meier analyses of efficacy outcomes. Shown are
Kaplan–Meier curves for the time−to−event analyses of death (Panel
A); time−to−event analyses of invasive mechanical ventilation
(Panel B); and time−to−event analyses of death in subgroups as
received tocilizumab, received pulse steroid, received both, received
none (Panel C).
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3.2. Treatments and outcomes
The treatments given to the patients and the secondary
outcome results are shown in Table 3 in a comparative
manner according to the groups. Treatments performed
in the ST group and TT group and their rates were
as follows: favipiravir treatment 41 (44.6%) patients
and 14 (28%) patients, respectively p = 0.079, daily 6
mg dexamethasone treatment for 14 (15.2%) patients
and 6 (12%) patients respectively p = 0.784, low dose
methylprednisolone treatment 53 (57.6%) patients and
33 (66%) patients, respectively p = 0.425, high dose
methylprednisolone treatment 20 (21.7%) patients and
22 (44%) patients respectively p = 0.010, Vitamin D use
81 (88%) patients and 47 (94%) patients respectively p =
0.379, Vitamin C use in 82 (89.1%) patients and 46 (91%)
patients respectively p = 0.770, Factor Xa inhibitor use in
75 (89.3%) patients and 44 (89.8%) patients respectively
p = 1.000, Immune Plasma treatment 25 (27.5%) patients
and 15 (30%) patients respectively p = 0.902, awake
prone position method 26 (28.3%) patients and 33 (66%)
patients respectively p < 0.001, vasopressor support in 27
(29.3%) patients and 16 (32%) patients respectively p =
0.891, sedation need in 40 (43.5%) patients and 35 (70%)
patients respectively p = 0.007. There were statistically
significant differences in treatments between the two
groups in the use of high-dose steroids, the awake prone
position, and the need for sedation (Table 3). There was
a statistically significant difference on the day basis in the
treatment durations (sedation, vasopressor, NIMV, IMV,
HFNC) due to the longer median length of stay in the
tocilizumab treatment group. In the secondary outcome
targets, 21 (22.8%) patients in the ST group and 12 (24%)
patients in the TT group developed acute kidney injury (p
= 1.000). Hepatic failure rate was 16.3% with 15 patients in
the ST group and 18% with 9 patients in the TT group (p
= 0.982). The rates of discharge of the patients from ICU
to services did not differ statistically between the ST group
and the TT group (55 patients [59.8%], 37 patients [74%],
p = 0.131, respectively).
4. Discussion
In our study, the clinical outcomes of tocilizumab
treatment performed in patients with hypoxic COVID-19
pneumonia who do not receive mechanical ventilation
support but have an indication for intensive care were
evaluated. Study analyses were carried out after it was
determined that the groups were standardized according
to the APACHE II and SOFA scores. This study showed
that the mortality rate of tocilizumab group (TT) was
lower compared to the standard therapy group (ST).
The results of our trial suggest that patients who are
most likely to benefit from tocilizumab have moderate
or severe disease (i.e. they have hypoxia but are not yet
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receiving mechanical ventilation) and that tocilizumab
may add to the potential benefit of antiviral treatment and
glucocorticoids. However, there was no decrease in the
undergoing to mechanical ventilation in the tocilizumab
treatment group. During intensive care period, 26 patients
(28.3%) in the ST group and 12 patients (24%) in the
TT group died. In our study, the distribution of patients
who received antiviral and low-dose steroid therapy was
balanced in both groups; however, the group that received
tocilizumab also received a significantly higher rate (44%)
of pulse steroids, which suggests that this group of patients
were treatment-resistant and more severe.
While negative results related to tocilizumab treatment
have been published on tocilizumab treatment at the
beginning of the pandemic process, the current data
and guidelines contain positive results on treatment
efficacy of tocilizumab [12,16]. Literature data, including
numerous studies such as COVACTA, EMPACTA,
BACC By TOCI, CORIMUNO − TOCI, RCT − TCZ −
COVID-19, revealed that tocilizumab does not provide a
survival advantage [11,13,17–19]. While the COVACTA
study was a randomized placebo-controlled study that
enrolled a group of patients from moderate hypoxia to
invasive mechanical ventilation, EMPACTA was similar
to our study which included patients who did not need
a mechanical ventilator; however, this study also showed
no difference in the incidence of death from any cause,
although it reduced the likelihood of progressing to
mechanical ventilation or death compared to placebo
and standard treatment [11,17]. The efficacy end point
of survival without invasive or noninvasive mechanical
ventilation by day 14 was achieved in the CORIMUNOTOCI-1 trial but without a mortality benefit at day 28
[18]. More recently, the RECOVERY study shows that
the benefits of tocilizumab extend to a broad group of
patients receiving oxygen, with or without other forms
of respiratory support, and that those benefits include a
reduction in the need for invasive mechanical ventilation.
RECOVERY study gives important results among these
studies in terms of being multi-centered, randomized
controlled, open-label and wide participation with 4116
patients. In this study, tocilizumab was administered to the
patients on any oxygen support with a rapid increase in
oxygen demand and a CRP level of ≥75 mg / l [12].
COVID-19 patients have a wide range of physiological
and biological diversity [20]; therefore, despite the
negative consequences, the succession of tocilizumab
studies has not ceased due to the visible and rapid clinical
improvements observed in some of the patient groups
that have not yet been clearly identified. Our study is
of importance because it has one of the first data about
tocilizumab results in patients with COVID-19 pneumonia
who need intensive care in Turkey. In our study, the effect
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Table 3. Comparison treatments and secondary outcomes of patients.*
Standart Treatment
(ST)
(N = 92)

Tocilizumab Treatmnet
(TT)
(N = 50)

Total
(N = 142)

p Value

Favipravir

41 (44.6)

14 (28)

55 (38.7)

0.079

Dexametasone – 6mg daily

14 (15.2)

6 (12)

20 (14.1)

0.784

Low dose metilprednisolone – < 1mg/kg/day

53 (57.6)

33 (66)

86 (60.6)

0.425

High dose metilprednisolone – > 250mg/day

20 (21.7)

22 (44)

42 (29.6)

0.010

D vitamin

81 (88)

47 (94)

128 (90.1)

0.379

C vitamin

82 (89.1)

46 (92)

128 (90.1)

0.770

Factor Xa inhibitors

75 (89.3)

44 (89.8)

119 (89.5)

1.000

Immunplasma

25 (27.5)

15 (30)

40 (28.4)

0.902

Prone position − awake

26 (28.3)

33 (66)

59 (41.5)

<0.001

Vasopressor support

27 (29.3)

16 (32)

43 (30.3)

0.891

Sedation support

40 (43.5)

35 (70)

75 (52.8)

0.007

Immune plasma dose − unit

1 (0 − 1)

0 (0 − 1)

1 (0 − 1)

0.515

Sedation − day

0 (0 − 5)

5 (0 − 8)

2 (0 − 6)

<0.001

Sedation free − day

4 (2 − 6)

6 (3 − 11)

4 (2 − 7)

<0.001

Vasopressors − day

0 (0 − 1)

0 (0 − 2.25)

0 (0 − 2)

0.613

Vasopressor free − day

4 (3 − 7)

11 (7 − 17)

6 (4 − 11)

<0.001

Non−invasive ventilation − day

0 (0 − 1)

0 (0 − 0.25)

0 (0 − 1)

0.918

Non−invasive ventilation free −day

5 (3 − 7.75)

11 (7 − 17.25)

7 (4 − 11.25)

<0.001

Invasive mechenical ventilation − day

4.5 (3 − 7)

11 (6 − 16)

6 (4 − 11)

<0.001

HFNC − day

2 (0 − 4.75)

7 (3.75 − 14)

3.5 (0 − 7.25)

<0.001

Development of AKI

21 (22.8)

12 (24)

33 (23.2)

1.000

Hepatic Failure

15 (16.3)

9 (18)

24 (16.9)

0.982

Discharge to wards

55 (59.8)

37 (74)

92 (64.8)

0.131

Characteristic
Treatments − no. (%)

Median treatments (IQR)

Outcomes − no. (%)

*Percentages may not total 100 because of rounding. IQR denotes interquartile range, HFNC high−flow nasal cannula, and AKI acute
kidney injury.

of tocilizumab treatment in patients especially who do not
need mechanical ventilation was investigated, and it was
observed that all-cause mortality in intensive care reduced
by 0.39 (CI 95%: 0.186–0.808). Although the tocilizumab
treatment patient group was equivalent to the standard
treatment group in terms of APACHE II and SOFA scores,
inflammatory markers such as Ferritin, CRP, LDH were
higher, and the first arrival P/F ratio (median 79.5) was
statistically significantly lower in the tocilizumab treatment
group. On the other hand, the decrease in mortality and
the inability to prevent mechanical ventilation in the
tocilizumab treatment group shows the successful results
of mechanical ventilation, although intubation is needed

in these patients. In the study, while all the tocilizumab
treatment patients received low-dose methylprednisolone
treatment, 19.7% received only tocilizumab without pulse
steroid therapy, and 14% received tocilizumab treatment
with pulse steroid. Only mortality of the tocilizumab
treatment group was found to be significantly lower than
the others (0.34 (CI 95%: 0.132–0.854)).
In the RECOVERY study, increased CRP was taken
into account as it correlates with IL-6 as an inflammatory
marker at follow-up [12,21]. Since IL-6 is not always a
workable parameter in our laboratory in the decision of
tocilizumab, we took as a base the level of markers such as
ferritin, CRP, LDH (without determining a certain cut-off
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and the elevation of any two markers is sufficient), rapid
increase in the patient’s O2 need and bilateral worsening
of infiltrations on chest radiography. Therefore, we
performed tocilizumab treatment in the early stages of
clinical progression.
The importance of this study is given as follows. Since it
is carried out in a single centered intensive care unit where
a single responsible person (pulmonology and intensive
care specialist) follows and arranges treatments for 24 h
(consultation was not requested from any department for
a treatment recommendation), there was no problem in
standardization. The limitations of our study were that
the study was a retrospective design and blood gas, and
oxygenation values were not recorded in patients just
before and after tocilizumab administration. In addition,
radiological improvement after tocilizumab administration
was not evaluated. Another limitation is that undesirable
outcomes at the patients such as secondary infections were
not evaluated.
In conclusion, tocilizumab reduces all cause mortality
in intensive care when used with low-dose steroid or
after pulse steroid in COVID-19 pneumonia patients
with varying degrees of hypoxia and evidence of systemic
inflammation. This benefit was found especially in
patients who were given tocilizumab in the early period
with clinical-radiological progression and increased

oxygen demand. We recommend that new studies with
a larger number of patients be planned prospectively in
standardized groups.
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